Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2016 - 2018)

Catalyst Pharmaceuticals filings provide 7 years of Current Deferred Revenue readings, the most recent being $33408.0 for Q4 2018.

  • On a quarterly basis, Current Deferred Revenue rose 39.14% to $33408.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $33408.0, a 39.14% increase, with the full-year FY2018 number at $33408.0, up 39.14% from a year prior.
  • Current Deferred Revenue hit $33408.0 in Q4 2018 for Catalyst Pharmaceuticals, up from $21914.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $33408.0 in Q4 2018 to a low of $3254.0 in Q1 2014.
  • Median Current Deferred Revenue over the past 5 years was $18094.0 (2016), compared with a mean of $16181.7.
  • Biggest five-year swings in Current Deferred Revenue: surged 335.14% in 2015 and later dropped 2.27% in 2018.
  • Catalyst Pharmaceuticals' Current Deferred Revenue stood at $4158.0 in 2014, then surged by 335.14% to $18093.0 in 2015, then rose by 0.01% to $18094.0 in 2016, then skyrocketed by 32.7% to $24011.0 in 2017, then soared by 39.14% to $33408.0 in 2018.
  • The last three reported values for Current Deferred Revenue were $33408.0 (Q4 2018), $21914.0 (Q3 2018), and $27184.0 (Q2 2018) per Business Quant data.